Target intelligence / Profile preview

Chromobox protein homolog 5 (CBX5) (CBX5)

Target
CBX5
Molecular classification
Histone modification reader, Chromobox family, Heterochromatin protein 1 (HP1) family, Transcription repressor
01

Overview

Chromobox protein homolog 5 (CBX5), commonly known as Heterochromatin Protein 1 alpha (HP1α), is a pivotal epigenetic reader that recognizes and binds to trimethylated lysine 9 on histone H3 (H3K9me3) via its N-terminal chromodomain (UniProt P45973). This interaction is essential for the formation and maintenance of constitutive heterochromatin, leading to the transcriptional silencing of specific genomic regions and ensuring genome stability through centromere and telomere organization (Wikipedia, 2024). Beyond gene silencing, CBX5 is involved in the DNA damage response and kinetochore assembly during mitosis (RefSeq, 2008). In clinical contexts, CBX5 is frequently overexpressed in various malignancies, such as glioblastoma and breast cancer, where it promotes tumor progression and chemoresistance (Connelly et al., 2016). Conversely, the loss of CBX5 has been identified as a driver of resistance to EGFR inhibitors in lung adenocarcinoma by upregulating the E2F1-BIRC5 axis (Bugide et al., 2023). CBX5 is also implicated in the activation of pathogenic fibroblasts in idiopathic pulmonary fibrosis (IPF), where its inhibition can promote metabolic reprogramming (NIH, 2025). Therapeutic development focuses on small-molecule inhibitors and peptidomimetics like UNC7047 and UNC7560, which target the chromodomain's aromatic cage to disrupt H3K9me3 binding and modulate gene expression (Simhadri et al., 2021).

Other names
Heterochromatin protein 1 alphaHP1 alphaHP1AHP1Hs alphaAntigen p25
02

Mechanism of action

Competitive inhibition of the chromodomain's aromatic cage to prevent binding to trimethylated lysine 9 of histone H3 (H3K9me3), leading to the derepression of silenced genes and alteration of chromatin structure.

03

Biological functions

Gene silencingHeterochromatin formationCentromere organizationDNA damage responseTelomere maintenanceKinetochore assembly
04

Disease associations

CancerLung adenocarcinomaGlioblastomaBreast cancerIdiopathic pulmonary fibrosis
05

Safety considerations

Off-target effects on other HP1 isoforms (CBX1, CBX3) due to high sequence homologyGlobal epigenetic dysregulationContext-dependent tumor suppressive vs. oncogenic rolesPotential to drive drug resistance (e.g., to EGFR inhibitors) upon loss of function
06

Interacting drugs

UNC7047

2 more in the full profile.

07

Biomarkers

CBX5 mRNA expressionCBX5 protein levelsH3K9me3 levelsBIRC5 (survivin) expressionE2F1 expression

Beyond the preview

Go deeper on Chromobox protein homolog 5 (CBX5) (CBX5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chromobox protein homolog 5 (CBX5) (CBX5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call